Below are the financial statements of Carl Zeiss Meditec, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of EUR | 2024 2023-10-01 - 2024-09-30 | 2023 |
|---|---|---|
| Revenue | 2,066.13a | 2,089.3a |
| Cost of sales | -977.5a | -883.54a |
| Gross profit | 1,088.63a | 1,205.77a |
| Selling and marketing expenses | -458.2a | -420.28a |
| General and administrative expenses | -111.01a | -83.78a |
| Research and development expenses | -343.09a | -349.28a |
| Other operating result | 18.12a | -4.31a |
| Earnings before interest and taxes (EBIT) | 194.45a | 348.12a |
| Earnings of investments carried at equity | -3.02a | -0.89a |
| Interest income | 22.4a | 28.11a |
| Interest expenses | -29.42a | -15.25a |
| Net interest from defined benefit pension plans | 0.88a | 0.94a |
| Foreign currency gains (+)/ losses (-), net | 11.58a | 38.2a |
| Other financial result | 44a | 13.33a |
| Earnings before income taxes (EBT) | 240.87a | 412.56a |
| Income taxes | -60.71a | -120.56a |
| Consolidated profit | 180.15a | 292.01a |
| Of which profit/loss attributable to shareholders of the parent company | 178.73a | 290.4a |
| Of which profit/loss attributable to non-controlling interests | 1.43a | 1.61a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.